97296 ⎘
Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Modulation of stimulatory and non-stimulatory myeloid cells
#2702JAM-C antibodies and methods for treatment of cancer
#2703Modified J-chain
#2704Blocking monoclonal antibodies to AGR2 and its receptor C4.4A
#2705Car-expressing NK-92 cells as cell therapeutic agents
#2706Antigen binding proteins that bind c-met
#2707Therapeutic CD47 antibodies
#2708Method of providing disease-specific binding molecules and targets
#2709Chimeric antigen receptor specific for SSEA4 antigen
#2710MODIFIED MICROBIAL TOXIN RECEPTOR FOR DELIVERING AGENTS INTO CELLS
#2711ANTI-TROP-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF
#2712Combination therapy for inducing immune response to disease
#2713Multivalent CD20-binding molecule comprising Shiga toxin A subunit effector polypeptides and enriched compositions thereof
#2714Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
#2715Antibodies directed against ICOS for treating graft-versus-host disease
#2716ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
#2717Bispecific EGFR/C-Met Antibodies
#2718Humanized anti-CD22 antibody
#2719ANTI-EPHRINB2 ANTIBODIES AND METHODS USING SAME
#2720Antibodies to M-CSF
#2721Anti-DLL3 antibody drug conjugates
#2722Cytotoxicity-inducing theraputic agent
#2723RSPO3 Binding Agents and Uses Thereof
#2724IGF-1R antibody and its use as addressing vehicle for the treatment of cancer
#2725Method of treating CD155 expressing cancers
#2726Anti PD-1 antibodies
#2727Composition for preventing or treating lung cancer comprising antibody against CD66C and chemotherapeutic agent
#2728Method of Treating Ovarian and Renal Cancer Using Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen
#2729Transgene genetic tags and methods of use
#2730Anti-DLL3 antibody drug conjugates for treating cancer
#2731Methods of making DLL3 antibody drug conjugates
#2732Methods of delivering DLL3 antibody drug conjugates
#2733Anti-DLL3 antibody drug conjugates
#2734Chemically-locked bispecific antibodies
#2735METHODS FOR TREATING CANCER
#2736Cancer-cell-specific anti-transmembrane protein 180 antibody, anticancer drug, and cancer testing method
#2737Antibodies that Bind to OX40 and Their Uses
#2738Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
#2739Construct for the delivery of a molecule into the cytoplasm of a cell
#2740Anti-c-Met/anti-Ang2 bispecific antibody
#2741T cell-redirected antigen-binding molecule for cells having immunosuppression function
#2742Anti CD84 antibodies, compositions comprising same and uses thereof
#2743ANTIBODIES AGAINST NERVE GROWTH FACTOR (NGF) WITH ENHANCED IN VIVO STABILITY
#2744Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
#2745ANNEXIN A2 AS IMMUNOLOGICAL TARGET
#2746Anti-GD2 antibodies
#2747Antibodies to CD40 with enhanced agonist activity
#2748Anti-CD74 antibodies, compositions comprising anti-CD74 antibodies and methods of using anti-CD74 antibodies
#2749Anti-PD-L1 antibodies and uses thereof
#2750Anti-PD-L1 antibodies and uses thereof
#2751Methods of Suppressing Rheumatoid Arthritis Using An Anti-IL-6 Antibody
#2752Therapeutic antibodies against ROR-1 protein and methods for use of same
#2753PROTEASE-ACTIVATABLE BISPECIFIC PROTEINS
#2754Bispecific binding molecules binding to VEGF and Ang2
#2755Anti-AGE antibodies for treating inflammation and auto-immune disorders
#2756BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#2757COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
#2758Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
#2759Anti-IL-1beta antibodies
#2760Anti-PDGF-B antibodies and methods of use
#2761T-cell redirecting bispecific antibodies for treatment of disease
#2762Cytotoxic and anti-mitotic compounds, and methods of using the same
#2763Anti-CD40 antibodies
#2764AGR2 BLOCKING ANTIBODY AND USE THEREOF
#2765Single-chain variable fragment anti-CD133 antibodies and uses thereof
#2766Heterodimeric antibody Fc-containing proteins and methods for production thereof
#2767HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2
#2768Anti-neurotensin antibodies and uses thereof
#2769Chimeric antigen receptor containing a toll-like receptor intracellular domain
#2770Interferon therapy
#2771Compositions to regulate renalase in the treatment of diseases and disorders
#2772Chimeric antigen receptor compositions
#2773Combination therapies with anti CD40 antibodies
#2774Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
#2775Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
#2776Anti-OSPA antibodies and methods of use
#2777Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
#2778Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#2779Bispecific T cell engaging antibody constructs
#2780Development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies
#2781Anti-epidermal growth factor receptor (EGFR) antibodies
#2782Antibody gene expression-secretion system
#2783Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof
#2784Methods of treatment using anti-GM-CSF antibodies
#2785Anti-neurotensin long fragment antibodies and uses thereof
#2786Immunoglobulin constant region Fc receptor binding agents
#2787Targeted conformationally-constrained kinked endosomal disrupting peptides
#2788Bispecific HER2 and CD3 binding molecules
#2789Antibodies specific for epidermal growth factor receptor variant III and their uses
#2790Chimeric antigen receptors targeting epidermal growth factor receptor variant III
#2791Anti-PD-1 antibody and use thereof
#2792ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF
#2793ANTI-NME ANTIBODY
#2794Anti-CD3 antibodies and methods of use
#2795Antibody Fc Mutants with Ablated Effector Functions
#2796Therapeutic method and medicament for HTLV-1 associated myelopathy
#2797Anti-FGFR3 antibodies and methods using same
#2798Anti-CD47 antibodies and methods of use
#2799CD33 antibodies and use of same to treat cancer
#2800Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens
#2801MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR TREATING CANCER CACHEXIA AND CANCER
#2802ANTIBODY BASED REAGENT THAT SPECIFICALLY RECOGNIZES TOXIC OLIGOMERIC FORM OF BETA-AMYLOID
#2803Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof
#2804Method of treatment for leukemia using an anti-IL1RAP antibody
#2805Multi-chain polypeptide-containing tri-specific binding molecules
#2806Antibody-albumin nanoparticle complexes comprising albumin, bevacizumab, and paclitaxel, and methods of making and using the same
#2807Nanoparticle complexes of paclitaxel, alemtuzumab, and albumin
#2808Nanoparticle complexes of paclitaxel, trastuzumab, and albumin
#2809Methods and compositions for the treatment of ocular diseases and disorders
#2810Bispecific T cell activating antigen binding molecules
#2811Methods of treating with anti-PSGL-1 antibodies
#2812Methods for manipulating phagocytosis mediated by CD47
#2813Antibodies and conjugates thereof
#2814BSL2v2c2-Ig polypeptides
#2815BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
#2816Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
#2817Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
#2818Rodent combinatorial antibody libraries
#2819BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#2820Anti-HER3 antibodies and uses thereof
#2821Single-Arm Monovalent Antibody Constructs and Uses Thereof
#2822Anti-HER2 antibodies and immunoconjugates
#2823Combination therapies with anti-CD38 antibodies
#2824Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
#2825Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
#2826Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
#2827Monoclonal antibodies to progastrin and their uses
#2828Stabilized angiopoietin-2 antibodies and uses thereof
#2829Antibodies for epidermal growth factor receptor 3 (HER3)
#2830Humanized antibodies against CD269 (BCMA)
#2831CD89 ACTIVATION IN THERAPY
#2832Compositions and methods for TCR reprogramming using fusion proteins
#2833Methods of treating autoimmune diseases
#2834Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof
#2835Anti-La antibodies and their use for immunotargeting
#2836Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#2837Antigen binding formats for use in therapeutic treatments or diagnostic assays
#2838Pan-HER antibody composition
#2839Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
#2840Drug regulated transgene expression
#2841Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases
#2842Anti-huLRRC15 antibody drug conjugates and methods for their use
#2843Site specific HER2 antibody drug conjugates
#2844Production of T cell retargeting hetero-dimeric immunoglobulins
#2845Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#2846Methods for achieving therapeutically effective doses of anti-CD47 agents
#2847CD33 specific chimeric antigen receptors for cancer immunotherapy
#2848Compositions and methods for the treatment of immune related diseases
#2849Chemically-locked bispecific antibodies
#2850Anti-DLL3 antibodies and drug conjugates for use in melanoma
#2851Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
#2852Anti-Jagged1 antibodies and methods of use
#2853HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR
#2854Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer
#2855CAR-expressing NK-92 cells as cell therapeutic agents
#2856IgE antibodies for the inhibition of tumor metastasis
#2857Uses of monoclonal antibody 8H9
#2858COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
#2859Antibody constructs for CD70 and CD3
#2860Method of treating bone disease
#2861Antibody molecule-drug conjugates and uses thereof
#2862Methods for treating cancer using nanoparticle complexes of paclitaxel, rituximab, and albumin
#2863Nanoparticle complexes of rituximab, albumin and pacltaxel
#2864Nanoparticle complexes of paclitaxel, cetuximab, and albumin, and methods of making the same
#2865Methods for treating cancer using nanoparticle complexes of paclitaxel, cetuximab, and albumin
#2866Nanoparticle complexes of paclitaxel, cetuximab, and albumin
#2867Methods of treating cancer with antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel
#2868Methods for treating CD52-expressing cancers using compositions comprising nanoparticle complexes of paclitaxel, alemtuzumab, and albumin
#2869ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF
#2870Anti-CD324 monoclonal antibodies and uses thereof
#2871Compositions and methods to treat solid tumors
#2872Treatment of eosinophil or mast cell related disorders
#2873High affinity antibodies that neutralize enterotoxin B
#2874MODIFIED ANTIBODY IN WHICH MOTIF COMPRISING CYSTEINE RESIDUE IS BOUND, MODIFIED ANTIBODY-DRUG CONJUGATE COMPRISING THE MODIFIED ANTIBODY, AND PRODUCTION METHOD FOR SAME
#2875Humanized antibodies that bind LGR5
#2876Antibodies against human CSF-1R and uses thereof
#2877Methods and compositions for treating systemic mastocytosis
#2878Anti-alpha-synuclein antibodies and methods of use
#2879Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
#2880Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
#2881Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
#2882Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
#2883MEDICAMENTS, USES AND METHODS
#2884Antagonists for abdominal vasopressin V2 receptor and uses thereof
#2885Intracellular delivery compounds
#2886Anti-PD-L1 antibodies, compositions and articles of manufacture
#2887Constructs having a SIRP-α domain or variant thereof
#2888COMBINATORIAL IMMUNOTHERAPY FOR PANCREATIC CANCER TREATMENT
#2889Methods and compositions for treating autoimmune and inflammatory conditions
#2890Carbohydrate antibodies, pharmaceutical compositions and uses thereof
#2891USE OF ANTIBODY CONJUGATES
#2892BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#2893BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#2894Methods of treating cancer using compositions of antibodies and carrier proteins with antibody pretreatment
#2895Combination therapy with glutaminase inhibitors and immuno-oncology agents
#2896Distinguishing antagonistic and agonistic anti B7-H1 antibodies
#2897Human-derived insecticidal gene and insecticidal peptide encoded thereby and application thereof
#2898Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
#2899Monoclonal antibodies to programmed death 1 (PD-1)
#2900Drug conjugates for delivering compounds to senescent cells
#2901MDR specific antibody
#2902Heterodimeric antibodies to CD3 X CD123
#2903Heterodimeric antibodies to CD3 X CD20
#2904Modulators and methods of use
#2905Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
#2906Anti-CD47 antibodies and methods of use
#2907Mesothelin-targeted chimeric antigen receptors and uses thereof
#2908Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
#2909Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
#2910ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF
#2911Compositions and methods for the diagnosis and treatment of tumor
#2912Bispecific tetravalent antibodies and methods of making and using thereof
#2913NOVEL MULTISPECIFIC MOLECULES AND NOVEL TREATMENT METHODS BASED ON SUCH MULTISPECIFIC MOLECULES
#2914Methods and compositions for treating Siglec-8 associated diseases
#2915Anti-malignant tumor agent
#2916Engineered antibody-interferon mutant fusion molecules
#2917Anti-EGFR antibodies and antibody drug conjugates
#2918Proteins specific for BAFF and B7RP1
#2919Chimeric antigen receptor
#2920Esophageal cancer marker and use thereof
#2921Selective immunodepletion of endogenous stem cell niche for engraftment
#2922Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment
#2923Humanized anti-HLA-DR antibodies
#2924Antibodies to TGF-beta
#2925Monoclonal antibody against human PrPc and use thereof
#2926Enhancing the therapeutic activity of an immune checkpoint inhibitor
#2927Heterodimeric proteins and methods for producing and purifying them
#2928Monoclonal antibodies for treatment of cancer
#2929PD-L1 antibodies
#2930Anti-CD79B antibodies and immunoconjugates and methods of use
#2931Bi-specific antibodies and uses thereof
#2932Pharmaceuticals in joint-linker configurations for treating pathological blood clots
#2933Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
#2934Fusion proteins for treating cancer and related methods
#2935Humanized antibodies against CEACAM1
#2936Endoglin antibodies
#2937Humanized monoclonal antibodies and methods of use
#2938Antibody constructs for FLT3 and CD3
#2939Antibody constructs for DLL3 and CD3
#2940TRIFUNCTIONAL ANTIGEN-BINDING MOLECULE
#2941Use of annexin A3 as a diagnostic and prognostic biomarker and therapeutic target for treating hepatocellular carcinoma
#2942Antibody drug conjugates
#2943Antibodies, antibody drug conjugates and methods of use
#2944Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
#2945Treatment of metastatic breast cancer
#2946Humanized and chimeric monoclonal antibodies to CD99
#2947Antibodies against human CSF-1R and uses thereof
#2948Anti-CD123 antibodies and conjugates and derivatives thereof
#2949Antibody constructs for EGFRVIII and CD3
#2950Antibody constructs for MSLN and CD3
#2951Anti-EPHRINB2 antibodies and methods using same
#2952Uses of a dual V region antibody-like protein
#2953Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof
#2954Checkpoint inhibitor and a whole cell for use in cancer therapy
#2955Immunoactivating antigen-binding molecule
#2956Multispecific GITR-binding fusion proteins and methods of use thereof
#2957Prolactin receptor binding proteins and uses thereof
#2958Antibodies that bind to MHC class I polypeptide-related sequence A
#2959T-cell redirecting bispecific antibodies for treatment of disease
#2960Combination therapy for inducing immune response to disease
#2961Anti-fibulin-3 antibodies and uses thereof
#2962Multivalent and multispecific DR5-binding fusion proteins
#2963Antibodies against human CSF-1R and uses thereof
#2964Anti-glucosaminidase passive immunization for infections
#2965Targeted drug delivery through affinity based linkers
#2966Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#2967Method for assaying soluble GPC3 protein
#2968Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
#2969Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
#2970Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
#2971Therapeutic peptides
#2972Monoclonal antibodies that modulate immunity to MTB and enhance immune clearance
#2973Cytotoxic antibody
#2974TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF
#2975Anti-CD33 antibodies and immunoconjugates
#2976Anti-DLL3 antibody drug conjugates for treating cancer
#2977Methods of treating multiple sclerosis using anti-CD20 antibodies
#2978PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
#2979Humanized anti-CD22 antibody
#2980Use of an IL-17/IL-23 bispecific antibody for treating inflammation
#2981Hybrid constant regions
#2982CYS80 conjugated immunoglobulins
#2983Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
#2984ANTIBODY FORMULATION
#2985Anti-CLL-1 antibodies and methods of use
#2986Soluble MIC neutralizing monoclonal antibody for treating cancer
#2987ANTI B7-H3 ANTIBODY
#2988Anti-CTLA-4 antibodies and methods of use thereof
#2989Human CD3 binding antibody
#2990Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
#2991Humanized and affinity matured antibodies to FcRH5 and methods of use
#2992Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
#2993Trifunctional T cell-antigen coupler and methods and uses thereof
#2994Method for treatment of blood tumor using anti-TIM-3 antibody
#2995KIDNEY DISEASE TARGETS AND USES THEREOF
#2996Modified microbial toxin receptor for delivering agents into cells
#2997Methods of Using Interleukin-10 for Treating Diseases and Disorders
#2998Acinetobacter baumannii antigens and the uses thereof
#2999Heterodimeric antibodies that bind CD3 and tumor antigens
#3000CA6 antigen-specific cytotoxic conjugate and methods of using the same